Avonex (interferon beta-1a), the drug most prescribed for people suffering from relapsing multiple sclerosis


Jacobs School of Medicine and Biomedical Sciences, the University at Buffalo


Lawrence Jacobs, MD, University at Buffalo Jacobs School of Medicine and Biomedical Sciences School of Medicine professor of neurology


Jacobs’ research showed that early treatment of multiple sclerosis with interferon beta-1a significantly reduced the rate of progression and impact of the disease, which often includes brain and nerve damage.


As early as 1981, Jacobs’ research showed results. In 2000, the New England Journal of Medicine published the results of a large-scale study led by Jacobs that described the benefits of beta-1a interferon in treating multiple sclerosis. The impact of this study prompted the Harvard Health Letter to name Jacobs’ research as one of the 10 leading health advances for 2000.